As of 1st July 2020, Lantus® (Insulin Glargine 100units/mL) was delisted from the PBS and replaced with Optisulin® (Insulin Glargine 100units/mL). The Lantus orderset has been updated to reflect this change and now also includes its biosimilar Semglee. The orderset provides guidance on appropriate choices for NEW and continuation therapy for patients

Things to note:

·         This updated orderset can be found by searching for either Lantus, Optisulin or Semglee

·         A new prescription is not required when transitioning to Optisulin®

·         Close blood glucose monitoring is recommended in the initial weeks of transition